Molecular switch between mammalian MLL complexes dictates response to Menin-MLL inhibition
Yadira M Soto-Feliciano,
Francisco J Sanchez-Rivera,
Douglas W Barrows,
Edward R Kastenhuber,
Mary Clare Beytagh,
X. Shirley Liu,
Andrei V. Krivtsov,
Elisa de Stanchina,
Richard M Stone,
Scott A Armstrong,
Scott W. Lowe,
C. David Allis
Posted 22 Oct 2021
bioRxiv DOI: 10.1101/2021.10.22.465184
Posted 22 Oct 2021
The chromatin adaptor Menin interacts with oncogenic fusion proteins encoded by MLL1-rearrangements (MLL1-r), and small molecules that disrupt these associations are currently in clinical trials for the treatment of leukemia. By integrating chromatin-focused and genome-wide CRISPR screens with genetic, pharmacological, and biochemical approaches in mouse and human systems, we discovered a molecular switch between the MLL1-Menin and MLL3/4-UTX chromatin modifying complexes that dictates response to Menin-MLL inhibitors. We show that MLL1-Menin safeguards leukemia survival by impeding binding of the MLL3/4-UTX complex at a subset of target gene promoters. Disrupting the interaction between Menin and MLL1 leads to UTX-dependent transcriptional activation of tumor suppressive genes, including factors associated with cell cycle arrest and cellular senescence. We show that this epigenetic mechanism is operative in murine and human models of AML, and clinical responses to Menin-MLL inhibition in primary human leukemia are also accompanied by induction of these tumor suppressive genes. We provide proof-of-concept in vivo evidence that this mechanism can be rationally exploited to design combination therapies using FDA-approved drugs (e.g. CDK4/6 inhibitors) to mitigate treatment resistance associated with MLL3/4-UTX complex mutations. These findings shed light on the context-dependent and often antagonistic roles that chromatin regulators exhibit in development and disease and provide mechanistic insight for rational design of targeted epigenetic therapies.
- Downloaded 1,821 times
- Download rankings, all-time:
- Site-wide: 12,011
- In cancer biology: 225
- Year to date:
- Site-wide: 1,414
- Since beginning of last month:
- Site-wide: 689
Downloads over time
Distribution of downloads per paper, site-wide
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!